Original Article from The New England Journal of Medicine — Oral Apixaban for the Treatment of Acute Venous Thromboembolism. Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary. Original Article from The New England Journal of Medicine — Apixaban in Patients with Atrial Fibrillation.
|Published (Last):||20 December 2010|
|PDF File Size:||1.10 Mb|
|ePub File Size:||6.98 Mb|
|Price:||Free* [*Free Regsitration Required]|
How Effective Are Guidelines?
FDA approves antidote for factor Xa inhibitors
N Engl J Med Dec 13 At 23 years of follow-up, life expectancy was nearly 3 years longer with prostatectomy than with watchful waiting. Gradishar, MD A perspective on the most important research in the field from the past year. J Clin Oncol Dec 7. The median duration of follow-up was 1. Major bleeding occurred more often with apixaban 3. Wenn Sie fortfahren, nehmen wir an, dass Sie mit der Verwendung von Cookies auf dieser Webseite einverstanden sind.
To address this issue, investigators conducted an industry-funded, randomized, placebo-controlled, double-blind apixbaan of the direct factor Xa inhibitor apixaban 2.
Blood Dec 3, Kulasekararaj AG et al. Please register or login here.
The rate of the primary outcome was 1. Genetic Testing for Breast Cancer: DOACs appear to be as effective as LMWH and are more acceptable to patients, but they pose apixabsn risks for bleeding and should be used cautiously in those with gastrointestinal malignancies, renal impairment, or thrombocytopenia.
N Engl J Med Dec 4; [e-pub]. Portola Pharmaceuticals first submitted the biologics license application BLA for andexanet alfa enjm December Blood Dec 3.
N Engl J Med Dec 4. Carrier M et al.
The rate of hemorrhagic stroke was 0. Apixaban to prevent venous thromboembolism in patients with cancer.
Apixaban versus warfarin in patients with atrial fibrillation.
Gradishar, MD Highlights of the latest research. Older patients with previously untreated disease had better outcomes with ibrutinib than with neejm.
The primary outcome was ischemic or hemorrhagic stroke or systemic embolism.
Ravulizumab was noninferior to eculizumab in both previously treated and treatment-naive patients. For additional information on andexanet alfa, visit https: This study is scheduled to start inwith results expected to be available in With its first BLA submission, Portola was seeking nejn for andexanet alfa as a reversal agent for patients anticoagulated with an oral or injectable factor Xa inhibitor—apixaban, rivaroxaban, edoxaban, alixaban enoxaparin—who experience serious uncontrolled or life-threatening bleeding or who require urgent or emergency surgery.
Vitamin K antagonists are highly effective in preventing nenm in patients with atrial fibrillation but have several limitations. Expert Opin Investig Drugs. Forty percent of patients with relapsed or refractory disease achieved complete remission.
Apixaban or placebo was given within 24 hours of starting chemotherapy and continued for 6 months. Continued FDA approval of andexanet alfa may be contingent upon post-marketing study results to demonstrate an improvement in hemostasis in patients taking rivaroxaban or apixaban who require reversal of anticoagulation. In this randomized, double-blind trial, we compared apixaban at a dose of 5 mg twice daily with warfarin target international normalized ratio, 2.
Apixabn post-marketing requirement is a trial in which patients will be randomized to receive either andexanet alfa or usual care.
Patients with active malignancies are at risk for VTE but do not always receive prophylactic anticoagulants because of concerns about bleeding, need for injections, and cost. N Engl J Med Dec Andexanet alfa is approved for use in patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed nenm to life-threatening or uncontrolled bleeding. Comment Patients with active malignancies apixbaan at risk for VTE but do not always receive prophylactic anticoagulants because of concerns about bleeding, need for injections, and cost.
N Engl J Med. This time, the company sought approval of the drug only for patients on apixaban or rivaroxaban who are experiencing uncontrolled or life-threatening bleeding.